Caris Life Sciences Inc. (CAI)
NASDAQ: CAIHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CAI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.04B
- P/E (TTM)
- 10.59
- Forward P/E
- 64.87
- EPS (TTM)
- $1.66
- Dividend yield
- None
- 52-week range
- 14.19 – 36.50
- Day range
- 17.27 – 18.42
- Volume / Avg
- 4.57M / 4.61M
- Beta
- —
- Shares outstanding
- 286.78M
52-week range
CAI stock today
Caris Life Sciences (CAI) closed at $17.58 on Nov 20, down 5.18% (-$0.96), versus the S&P 500's 3.70% decline. Shares are 51.8% below their 52-week high of $36.50, set on Oct 28, 2026 and 23.9% above the 52-week low of $14.19, near the bottom of the past year's range. CAI is down 34.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 27.0%.
At 10.6x trailing earnings, Caris Life Sciences trades below the peer-group median of 27.1x. Its forward P/E of 64.9x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Caris Life Sciences
Company profileCaris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Dr. David Dean Halbert M.D.
- Headquarters
- Irving, TX
- Employees
- 1,846
- IPO year
- 2025
- Website
- carislifesciences.com
Financial highlights
Full financialsIn fiscal 2025, Caris Life Sciences generated $812.0 million in revenue, up 97.0% from fiscal 2024, its 2nd consecutive year of revenue growth. Caris Life Sciences reported a net loss of $68.1 million, compared with a loss of $281.9 million a year earlier. Operating margin was 5.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $812.03M | $412.26M | $306.13M |
| Growth | +96.97% | +34.67% | — |
| Net income | $-68.09M | $-281.89M | $-341.42M |
| EPS (diluted) | $-3.22 | $-10.66 | $-13.24 |
Analyst forecast
ForecastConsensus (14 analysts)
buy
Avg. price target
$34.23+94.71%
- Strong buy 1
- Buy 9
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $0.05 vs $0.03
- Surprise
- +66.67%
CAI news
All CAI news- Why is Caris Life Sciences stock rallying today?Investing.com
- BTSG vs. CAI: Which Stock Should Value Investors Buy Now?NasdaqBTSG, CAI
- Caris Life (CAI) Q3 2026 Earnings Call TranscriptNasdaqCAI, WSO.B
- Caris Q3 Net Income Declines 37% Despite 27% Revenue Growth; Raises FY26 OutlookNasdaqCAI, HEI.A
- Caris Q3 Profit Falls On Higher Expenses; Raises FY26 Revenue Guidance After 27% Revenue GrowthNasdaqCAI, BRK.A
- Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call TranscriptSeeking Alpha
- Caris Life Sciences,?Inc. (CAI) Q3 Earnings and Revenues Top EstimatesNasdaqCAI, NTRA
- Caris Life Sciences, Inc. GAAP EPS of $0.05 beats by $0.02, revenue of $275.4M beats by $20.06MSeeking Alpha
Caris Life Sciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CONConcentra Group Holdings Parent Inc. | 41.84 | +0.94% | $5.26B | vs CAI |
| RDNTRadNet Inc. | 69.71 | +0.29% | $5.49B | vs CAI |
| GRALGRAIL Inc. | 99.25 | -5.33% | $4.46B | vs CAI |
| BLLNBillionToOne Inc. Class A | 89.92 | -0.31% | $4.30B | vs CAI |
| CDNACareDx Inc. | 70.00 | -2.67% | $3.68B | vs CAI |
| ACHCAcadia Healthcare Company Inc. | 34.60 | +0.38% | $3.22B | vs CAI |
| CELCCelcuity Inc. | 53.35 | -5.26% | $2.61B | vs CAI |
| OSCROscar Health Inc. Class A | 24.73 | -5.50% | $7.68B | vs CAI |
Indexes, lists and sector
Caris Life Sciences stock FAQ
What is Caris Life Sciences's stock price today?
CAI last traded at $17.58 as of Nov 20, 4:00 PM EST, down 5.18% on the day. Prices are delayed at least 15 minutes.
What is CAI's P/E ratio?
CAI trades at a trailing P/E ratio of 10.59 and a forward P/E of 64.87, compared with a median of 27.1 for its closest peers.
Who is Caris Life Sciences's CEO?
Dr. David Dean Halbert M.D. is the chief executive officer of Caris Life Sciences Inc., which has about 1,846 employees.
What is the CAI 52-week high?
The 52-week high for CAI is $36.50 and the 52-week low is $14.19. The stock is currently 51.8% below its high.